Acute promyelocytic leukaemia (APML) is a biologically and clinically distinct variant of AML, currently classified as acute myeloid leukaemia with recurrent cytogenetic anomalies t(15;17) (q22;q21), promyelocytic leukaemia-retinoic acid receptor alpha, diagnosis regardless of blast count in the World Health Organization classification system. It is one of the curable malignancies, has a unique clinical presentation, often with disseminated intravascular coagulation, and has a targeted therapy for its treatment in the form of all trans retinoic acid (ATRA) and arsenic trioxide (ATO). Here, we report a complex type of variant APML t(3;15) (q26;q13), the need for conventional karyotyping for diagnosing such rare variants, and its response to ATRA and ATO.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3757957PMC
http://dx.doi.org/10.3332/ecancer.2013.340DOI Listing

Publication Analysis

Top Keywords

t315 q26q13
8
acute promyelocytic
8
promyelocytic leukaemia
8
complex variant
4
variant t315
4
q26q13 representing
4
representing cryptic/masked
4
cryptic/masked acute
4
leukaemia novel
4
novel breakpoint
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!